SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Jubilant Pharmova Ltd (JUBLPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530019 NSE: JUBLPHARMA Pharmaceuticals & Drugs | Small Cap | Jubilant Pharmova Share Price

₹969.75 -10.85 (-1.11%)

As on 04-Jun'26 16:59

Jubilant Pharmova Ltd (JUBLPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530019 NSE: JUBLPHARMA Pharmaceuticals & Drugs | Small Cap | Jubilant Pharmova Share Price

₹969.75 -10.85 (-1.11%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹15,446 Cr.
Current Price
₹969.8
52-Week Low / High
₹784 / 1,250
TTM EPS
₹1.3
TTM Sales
₹263 Cr.
Book Value per Share
₹145.2
P/E Ratio
776.20
Higher than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
6.68
Higher than its 5-year historical median
Price to Sales (P/S)
58.64
Higher than its 5-year historical median
EV/EBITDA
302.46
Higher than its 5-year historical median
Dividend Yield
0.56%
Profitability Efficiency
Return on Equity (ROE)
0.82%
Underperforms industry median
Return on Capital Employed (ROCE)
2.52%
Underperforms industry median
Return on Assets (ROA)
0.65%
Operating Profit Margin
4.5%
Net Profit Margin
2.57%
Gross Profit Margin
13.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-4.97%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
94.55%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-39.24%
Asset Quality
Promoter Holding
47.68%
Pledged shares (%) of Promoter's holding (%)
5.40%
Reserves
₹2,296 Cr.
Equity
₹15.9 Cr.
Face Value
₹1
All Time Low / High
₹3.51 / 1309.00

Jubilant Pharmova stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Locked
Login to view analysis.

Valuation

Locked
Login to view analysis.

Price Trend

Locked
Login to view analysis.
Q.1 Is Jubilant Pharmova Ltd a good quality company?
Jubilant Pharmova Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Jubilant Pharmova Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Jubilant Pharmova Ltd vs industry peers?
Jubilant Pharmova Ltd revenue CAGR is -24.99%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Jubilant Pharmova Ltd?
Promoters hold 47.68% of the Jubilant Pharmova Ltd, with 5.40% of their stake pledged, indicating low pledge risk.
Q.1 Stock return of Jubilant Pharmova Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.6% based on the current price.
View More

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jubilant Pharmova Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ7.1%7.6%13.6%8.1%10.1%11.8%4.4%3.7%2.6%2.5%-
Value Creation
Index ⓘ		-0.5-0.40.0-0.4-0.3-0.1-0.7-0.7-0.8-0.8-

Growth Parameters ⓘ
Sales ⓘ2,6562,4913,3063,4393,1402,710726810785746263
Sales YoY Gr.--6.2%32.7%4%-8.7%-13.7%-73.2%11.6%-3.1%-5%-
Adj EPS ⓘ4.84.816.110.320.613.55.13.121.81.3
YoY Gr.-0.2%234.6%-35.7%99.4%-34.6%-62%-39.8%-33.8%-14.2%-
BVPS (₹) ⓘ126.3128.2141.2146.9163.780.5153.1151.6148.6145145.2
Adj Net
Profit ⓘ		76.476.425616532821581.649.132.527.820
Cash Flow from Ops. ⓘ164419558182317608-3.6-65.1143136-
Debt/CF from Ops. ⓘ114.12.69.46.20.8-49-4.62.42.3-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ-13.2%-25%0.9%-5%
Adj EPS ⓘ-10.6%-38.9%-30.1%-14.2%
BVPSⓘ1.6%-2.4%-1.8%-2.4%
Share Price 10.6% 3% 42.2% -15%

Key Financial Parameters ⓘ

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		3.93.811.97.213.3114.421.41.20.9
Op. Profit
Mgn % ⓘ		11.91316.41012.115.81.10.42.34.518.5
Net Profit
Mgn % ⓘ		2.93.17.74.810.57.911.26.14.13.77.6
Debt to
Equity ⓘ		0.90.80.60.70.80.40.10.10.20.10
Working Cap
Days ⓘ		19515413313916110213925026225735
Cash Conv.
Cycle ⓘ		40442328412467136142137-5

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales2,6562,4913,3063,4393,1402,709726810785746
Operating Expenses ⓘ + 2,3442,1732,7673,1182,7692,282719807768714
Manufacturing Costs513475568617640499103125129140
Material Costs1,4531,3101,7712,0531,6841,450332415356276
Employee Cost 216226264266265221164167190203
Other Costs ⓘ 1621621631831791131211009495
Operating Profit ⓘ 312318539321371427631732
Operating Profit Margin (%) 11.8%12.8%16.3%9.3%11.8%15.8%0.9%0.4%2.1%4.3%
Other Income ⓘ + 6252467817348126138103100
Exceptional Items ⓘ 0000-20000-11
Interest ⓘ 20117413512913610211193030
Depreciation ⓘ 8781838610710037434853
Profit Before Tax ⓘ 8611536818329927385794238
Tax ⓘ 133510436-22594291018
Profit After Tax 737926314832121480503219
PAT Margin (%) 2.8%3.2%8.0%4.3%10.2%7.9%11.1%6.2%4.0%2.6%
Adjusted EPS (₹)4.65.016.59.320.213.55.13.12.01.2
Dividend Payout Ratio (%)65.50%60.30%18.10%48.60%24.80%37.10%98.90%159.30%251.60%414.10%

Valuation of Jubilant Pharmova - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 2,0142,0422,2492,3402,6071,2822,4392,4112,3622,305
Share Capital ⓘ 16161616161616161616
Reserves ⓘ 1,9982,0262,2332,3242,5911,2672,4232,3952,3462,289
Debt +1,5691,5641,2501,6021,951493174302340292
Long Term Debt1,1151,3871,0591,1401,328420174174247233
Short Term Debt4541771914636237301289460
Minority Interest0000000000
Trade Payables36448774959661916159164148155
Others Liabilities ⓘ 3592883763252575389115129146
Total Liabilities ⓘ 4,3064,3824,6254,8645,4331,8452,8602,9912,9802,898

Fixed Assets

Net Fixed Assets ⓘ +1,4151,4211,4381,4911,865127637687711699
Gross Block1,5021,5871,6851,8222,2881498679471,0091,036
Accumulated Depreciation8616624733142422230260297337
CWIP ⓘ 366511528459035473719
Investments ⓘ 1,7091,7101,7061,7641,7641,6461,6461,6571,6571,657
Inventories4754545864926560323314251232
Trade Receivables3413864944814250131189194206
Cash Equivalents 417738352584023113613
Others Assets ⓘ 2882692483174063166879472
Total Assets ⓘ 4,3064,3824,6254,8645,4331,8452,8602,9912,9802,898

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 164419558182317608-4-65143136
PBT ⓘ 8611536818329927385794238
Adjustment ⓘ 260230207159103196-49-354879
Changes in Working Capital ⓘ -1688042-112-65181-3-926631
Tax Paid ⓘ -14-5-58-49-20-43-19-17-12-13
Cash Flow From Investing Activity ⓘ + 522-43-127-285-1981789331-40-2
Capex -68-103-141-281-197-92-37-59-67-21
Net Investments 41300001290-9-7-1
Others ⓘ 1776014-4-1142130993420
Cash Flow From Financing Activity ⓘ + -784-338-47085-41-782-10723-78-157
Net Proceeds from Shares ⓘ 0000000000
Net Proceeds from Borrowing ⓘ -520-156-2860-160-13600100-3
Interest Paid ⓘ -201-170-138-134-147-102-11-18-30-30
Dividend Paid ⓘ -51-53-55-56-153-1-80-80-80-80
Others ⓘ -13419275419-542-16121-68-44
Net Cash Flow ⓘ -9838-40-18785-18-1225-24

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)3.693.912.286.4312.9811.034.332.061.320.82
ROCE (%)7.137.6413.578.110.111.824.363.672.642.52
Asset Turnover Ratio0.580.60.740.720.610.740.310.280.260.25
PAT to CFO Conversion(x)2.255.32.121.230.992.84-0.05-1.34.477.16
Working Capital Days
Receivable Days43.2050.604851.7052.70065.7071.908998
Inventory Days64.8064.7056.8057.2066.700162.50143.50131.30118.30
Payable Days109.50118.60127.40119.60131.6079.8095.80142.10160.50200.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.005.405.405.40
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Jubilant Pharmova Ltd FAQs

The current trading price of Jubilant Pharmova on 04-Jun-2026 16:59 is ₹969.8.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Jubilant Pharmova stood at ₹15,446.3 Cr

The latest P/E ratio of Jubilant Pharmova as of 03-Jun-2026 is 776.2.

The latest P/B ratio of Jubilant Pharmova as of 03-Jun-2026 is 6.68.

The 52-week high of Jubilant Pharmova is ₹1,250 and the 52-week low is ₹783.8.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jubilant Pharmova is ₹263 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jubilant Pharmova Ltd is a average quality company.

The key valuation ratios of Jubilant Pharmova Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Jubilant Pharmova Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Jubilant Pharmova Ltd

Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.

The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.

The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.

Business area of the company

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Business segments

  • Pharmaceuticals
  • Life Science Ingredients
  • Drug Discovery & Development Solutions
  • India Branded Pharmaceuticals

Awards

2012

  • NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
  • Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.

2013

  • Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
  • Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
  • Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.

2014

  • Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
  • BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
  • Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
  • IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
  • Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
  • Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.

2015

  • Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
  • Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.

2016

  • Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
  • Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
  • 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.

2017

  • Social Entrepreneur of the Year (SEOY)-India Award 2017.
  • Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
  • ‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×